Beta
Abciximab
medication Under reviewAbciximab is a chimeric monoclonal antibody fragment that targets the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen binding and thereby inhibiting platelet aggregation. Administered intravenously, it rapidly achieves high receptor occupancy, leading to profound and sustained antiplatelet effects during its infusion period. This mechanism disrupts the final common pathway of platelet activation, making it effective for acute settings requiring immediate platelet inhibition.
Research summary
Scientific evidence from studies in healthy human subjects demonstrates that abciximab effectively blocks platelet glycoprotein IIb/IIIa receptors and inhibits platelet aggregation in a concentration-dependent manner. Research consensus indicates reliable pharmacodynamics in healthy individuals, with clearance and effect profiles establishing thresholds for substantial inhibition, though applications remain centered on procedural contexts rather than general supplementation.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research
No studies found yet. Request research to discover relevant studies.
Community updates
No updates yet for this supplement.
Be the first to share your experience!